Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Oncolytics Biotech® to Host Conference Call March 3

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Feb 22, 2022 11:09am

213 Views

Post# 34450247

RE:Oncolytics Biotech® to Host Conference Call March 3

Hello Snow, it does say corporate update for the 4th quarter and full year 2021, they may decide to update further if they want to give shareholders something to look forward to but totally at their discretion. We already know what has happened in 2021.

<< Previous

Bullboard Posts

Next >>

This gambling tech stock might be the safest bet you’ll make this year